Status:

COMPLETED

Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)

Lead Sponsor:

Mochida Pharmaceutical Company, Ltd.

Collaborating Sponsors:

Fuji Yakuhin Co., Ltd.

Conditions:

Hepatic Insufficiency

Healthy

Eligibility:

All Genders

20+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety after single oral administration of FYU-981 to subjects with hepatic insufficiency and with normal hepatic func...

Eligibility Criteria

Inclusion

  • Adult healthy subjects or adult cirrhosis patients
  • Body mass index: \>=18.5 and \<30.0

Exclusion

  • Subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study (except for cirrhosis patients with hepatic diseases)

Key Trial Info

Start Date :

October 6 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 25 2018

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT03306667

Start Date

October 6 2017

End Date

June 25 2018

Last Update

September 24 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mochida Investigational sites

Tokyo, Japan

Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency) | DecenTrialz